All In Biotech

Drug Trial Radar · NCT04565275

A Study of ICP-192 in Patients With Advanced Solid Tumors

A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations

Last checked: Nov 19, 2026Latest source record: Mar 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

45

Planned (sponsor's estimate)

Start

Feb 1, 2021

Primary completion

Nov 30, 2023

Study completion Apr 15, 2024

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.

Conditions

  • Advanced Solid Tumors
  • Urothelial Carcinoma
  • Cholangiocarcinoma

Interventions

  • Drug ICP-192Drug

    1. Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the "3+3" dose escalation scheme 2. Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 3 years
  2. MTDTime frame: Up to 3 years
  3. OBDTime frame: Up to 3 years
  4. RP2DTime frame: Up to 3 years
  5. ORRTime frame: Up to 3 years

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Oncology

    Tucson, Arizona · Recruiting

  • University of California, San Diego (UCSD) - Moores Cancer Center

    La Jolla, California · Recruiting

  • Rocky Mountain Cancer Centers

    Aurora, Colorado · Recruiting

  • Mid Florida Hematology and Oncology

    Orange City, Florida · Not yet recruiting

  • Minnesota Oncology Hematology

    Minneapolis, Minnesota · Recruiting

  • Clinical Research Alliance

    Lake Success, New York · Recruiting

  • Rutgers Cancer Institute of New Jersey

    The Bronx, New York · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Macquarie University Hospital

    Macquarie Park, New South Wales, Australia · Recruiting

  • GenesisCare - North Shore

    St Leonards, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Recruiting

  • Monash Medical Centre Clayton

    Clayton, Victoria, Australia · Recruiting

  • Peninsula & South Eastern Haematology & Oncology Group

    Frankston, Victoria, Australia · Recruiting

  • Olivia Newton-John Cancer Research Institute

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.